Yong-Kil Hong

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Roger Stupp, Monika E. Hegi, Thierry Gorlia et al. · The Lancet Oncology · 2014 · 1K citations

Medicine, Oncology, Pharmacotherapy +14

The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells

Seung Woo Lee, Hyun-Kyung Kim, Na Hyeon Lee et al. · Cancer Letters · 2015 · 116 citations

Medicine, Cancer Biology, Oncology +17

Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model

Tai‐Gyu Kim, Chang-Hyun Kim, Jungsun Park et al. · Clinical and Vaccine Immunology · 2009 · 72 citations · Full text

Medicine, Immunology, Oncology +17

Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults

Michael Weller, Émilie Le Rhun, Martin J. van den Bent et al. · Neuro-Oncology · 2023 · 51 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients

Jiheun Han, Yong-Kil Hong, Youn Soo Lee · Journal of Pathology and Translational Medicine · 2016 · 47 citations · Full text

Medicine, Immunology, Oncology +17